Liquidia Technologies Inc (NASDAQ:LQDA) — Market Cap & Net Worth
Market Cap & Net Worth: Liquidia Technologies Inc (LQDA)
Liquidia Technologies Inc (NASDAQ:LQDA) has a market capitalization of $7.24 Billion ($7.24 Billion) as of July 31, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #2758 globally and #990 in its home market, demonstrating a -0.28% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Liquidia Technologies Inc's stock price $86.80 by its total outstanding shares 88928099 (88.93 Million). See LQDA capital reinvestment ratio to understand how much of operating cash flow is reinvested back into capital assets.
Liquidia Technologies Inc Market Cap History: 2018 to 2026
Liquidia Technologies Inc's market capitalization history from 2018 to 2026. Data shows growth from $1.93 Billion to $7.72 Billion (29.25% CAGR).
Index Memberships
Liquidia Technologies Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.47 Trillion | 0.29% | #62 of 976 |
|
NASDAQ Composite
IXIC
|
$39.70 Trillion | 0.02% | #312 of 3165 |
Weight: Liquidia Technologies Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Liquidia Technologies Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Liquidia Technologies Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
19.37x
Liquidia Technologies Inc's market cap is 19.37 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2018 | $1.93 Billion | $2.71 Million | -$53.14 Million | 711.56x | N/A |
| 2019 | $380.17 Million | $8.07 Million | -$47.58 Million | 47.10x | N/A |
| 2020 | $262.34 Million | $739.63K | -$59.76 Million | 354.69x | N/A |
| 2021 | $433.08 Million | $12.85 Million | -$34.58 Million | 33.69x | N/A |
| 2022 | $566.47 Million | $15.94 Million | -$41.02 Million | 35.55x | N/A |
| 2023 | $1.07 Billion | $17.49 Million | -$78.50 Million | 61.17x | N/A |
| 2024 | $1.05 Billion | $14.00 Million | -$130.39 Million | 74.72x | N/A |
| 2025 | $3.07 Billion | $158.32 Million | -$68.92 Million | 19.37x | N/A |
Competitor Companies of LQDA by Market Capitalization
Companies near Liquidia Technologies Inc in the global market cap rankings as of July 31, 2026.
Key companies related to Liquidia Technologies Inc by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #499 globally with a market cap of $52.60 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #516 globally with a market cap of $51.01 Billion USD ( CN¥348.61 Billion CNY).
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #543 globally with a market cap of $48.78 Billion USD.
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #614 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #499 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #516 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $51.01 Billion | CN¥54.65 |
| #543 | GALDERMA GROUP AG | NYSE:GALDY | $48.78 Billion | $45.10 |
| #614 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €15.50 |
Liquidia Technologies Inc Historical Marketcap From 2018 to 2026
Between 2018 and today, Liquidia Technologies Inc's market cap moved from $1.93 Billion to $ 7.72 Billion, with a yearly change of 29.25%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $7.72 Billion | +151.67% |
| 2025 | $3.07 Billion | +193.28% |
| 2024 | $1.05 Billion | -2.24% |
| 2023 | $1.07 Billion | +88.85% |
| 2022 | $566.47 Million | +30.80% |
| 2021 | $433.08 Million | +65.08% |
| 2020 | $262.34 Million | -30.99% |
| 2019 | $380.17 Million | -80.26% |
| 2018 | $1.93 Billion | -- |
End of Day Market Cap According to Different Sources
On Jul 31st, 2026 the market cap of Liquidia Technologies Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $7.24 Billion USD |
| MoneyControl | $7.24 Billion USD |
| MarketWatch | $7.24 Billion USD |
| marketcap.company | $7.24 Billion USD |
| Reuters | $7.24 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Liquidia Technologies Inc
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for rare cardiopulmonary diseases in the United States. The company's lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung diseas… Read more